Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy.

Literature DB >> 10991890

Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy.

D P Kontoyiannis¹, R E Lewis, N Sagar, G May, R A Prince, K V Rolston.

Abstract

We examined an E-test-based strategy for testing the combination of itraconazole and amphotericin B, the latter given either sequentially or concomitantly, in isolates of Aspergillus fumigatus. An antagonistic interaction between the two drugs was noted, especially with the sequential administration of amphotericin B. This in vitro antagonism was reversible.

Entities: Chemical Species

Mesh：

Substances：

Year: 2000 PMID： 10991890 PMCID： PMC90181 DOI： 10.1128/AAC.44.10.2915-2918.2000

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

12 in total

Review 1. Problems of antifungal in vitro testing in Aspergillus fumigatus.

Authors: A Espinel-Ingroff
Journal: Contrib Microbiol Date: 1999

2. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents.

Authors: D W Denning; L H Hanson; A M Perlman; D A Stevens
Journal: Diagn Microbiol Infect Dis Date: 1992-01 Impact factor: 2.803

Review 3. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.

Authors: T J Walsh; J W Hiemenz; E Anaissie
Journal: Infect Dis Clin North Am Date: 1996-06 Impact factor: 5.982

Review 4. Therapeutic outcome in invasive aspergillosis.

Authors: D W Denning
Journal: Clin Infect Dis Date: 1996-09 Impact factor: 9.079

Review 5. Use of amphotericin B with azole antifungal drugs: what are we doing?

Authors: A M Sugar
Journal: Antimicrob Agents Chemother Date: 1995-09 Impact factor: 5.191

6. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.

Authors: J L Harousseau; A W Dekker; A Stamatoullas-Bastard; A Fassas; W Linkesch; J Gouveia; R De Bock; M Rovira; W F Seifert; H Joosen; M Peeters; K De Beule
Journal: Antimicrob Agents Chemother Date: 2000-07 Impact factor: 5.191

7. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.

Authors: R E Lewis; B C Lund; M E Klepser; E J Ernst; M A Pfaller
Journal: Antimicrob Agents Chemother Date: 1998-06 Impact factor: 5.191

8. Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus.

Authors: S Maesaki; S Kohno; M Kaku; H Koga; K Hara
Journal: Antimicrob Agents Chemother Date: 1994-12 Impact factor: 5.191

Review 9. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors: B D Alexander; J R Perfect
Journal: Drugs Date: 1997-11 Impact factor: 9.546

10. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.

Authors: A Espinel-Ingroff; K Dawson; M Pfaller; E Anaissie; B Breslin; D Dixon; A Fothergill; V Paetznick; J Peter; M Rinaldi
Journal: Antimicrob Agents Chemother Date: 1995-02 Impact factor: 5.191

17 in total

1. Challenges in designing animal studies to detect antagonism of polyene activity.

Authors: Russell E Lewis; Dimitrios P Kontoyiannis; Dimitrios P Kantoyiannis
Journal: Antimicrob Agents Chemother Date: 2004-08 Impact factor: 5.191

Review 2. Combination antifungal therapy.

Authors: Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191

Review 3. Aspergillus infections in transplant recipients.

Authors: Nina Singh; David L Paterson
Journal: Clin Microbiol Rev Date: 2005-01 Impact factor: 26.132

4. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole.

Authors: Georgios Chamilos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal: Antimicrob Agents Chemother Date: 2006-01 Impact factor: 5.191

Review 5. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors: Romuald Bellmann; Piotr Smuszkiewicz
Journal: Infection Date: 2017-07-12 Impact factor: 3.553

6. Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.

Authors: Anne-Pauline Bellanger; Nathaniel D Albert; Russell E Lewis; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal: Antimicrob Agents Chemother Date: 2015-09-21 Impact factor: 5.191

Review 7. Combination treatment of invasive fungal infections.

Authors: Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal: Clin Microbiol Rev Date: 2005-01 Impact factor: 26.132

8. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.

Authors: William R Kirkpatrick; Brent J Coco; Thomas F Patterson
Journal: Antimicrob Agents Chemother Date: 2006-04 Impact factor: 5.191

9. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii.

Authors: Julliana Ribeiro Alves Santos; Ludmila Ferreira Gouveia; Erika Linzi Silva Taylor; Maria Aparecida Resende-Stoianoff; Gerson Antônio Pianetti; Isabela Costa César; Daniel Assis Santos
Journal: Antimicrob Agents Chemother Date: 2012-01-30 Impact factor: 5.191

10. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors: Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal: Antimicrob Agents Chemother Date: 2002-10 Impact factor: 5.191